{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:24:12Z","timestamp":1760145852917,"version":"build-2065373602"},"reference-count":18,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>A solitary bone plasmacytoma is a rare tumor. Intrahepatic cholangiocarcinoma is the second most common primary liver cancer after hepatocellular carcinoma. We present the case of a 48-year-old female patient who consulted for recent back pain, with a final diagnosis of T10 solitary plasmacytoma and synchronous intrahepatic cholangiocarcinoma. Imaging suggested cholangiocarcinoma with bone metastasis. The patient underwent neurosurgical management with laminectomy, arthrodesis, and arthrectomy, with biopsies revealing monotypic kappa plasmacytic proliferation. Liver biopsies revealed an adenocarcinoma with expression of cytokeratin 19, cytokeratin 7, N-cadherin, and high expression of carbonic anydrase IX. The plasmacytoma was treated with external radiotherapy. The cholangiocarcinoma was treated with selective internal radiation therapy and concomitant systemic treatment with combinations of cisplatin and durvalumab, with capecitabine during radiotherapy, switched for gemcitabine after completion of irradiation. One year after initial management, imaging revealed a partial metabolic response of the intrahepatic cholangiocarcinoma, and a complete metabolic response of the plasmacytoma. This case illustrates the importance of not ignoring two primary tumors and the management of two concomitant treatments exploiting potential therapeutic synergies and limiting expected toxicities.<\/jats:p>","DOI":"10.3390\/curroncol31090382","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T02:25:49Z","timestamp":1725416749000},"page":"5164-5170","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report of Concomitant Diagnosis of Locally Advanced Intrahepatic Cholangiocarcinoma and Solitary Plasmacytoma of T11 Vertebra: Impact on Diagnostic and Clinical Management"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8421-3182","authenticated-orcid":false,"given":"Yann","family":"Touchefeu","sequence":"first","affiliation":[{"name":"Inserm CIC 1413, H\u00e9pato-Gastroent\u00e9rologie, Institut des Maladies de l\u2019Appareil Digestif (IMAD), CHU Nantes, Universit\u00e9 de Nantes, F-44000 Nantes, France"},{"name":"CRCI2NA, INSERM UMR1307, CNRS-ERL6075, Universit\u00e9 de Nantes, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Barbaud","sequence":"additional","affiliation":[{"name":"CRCI2NA, INSERM UMR1307, CNRS-ERL6075, M\u00e9decine Nucl\u00e9aire, CHU Nantes, Universit\u00e9 de Nantes, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Prin-Felix","sequence":"additional","affiliation":[{"name":"Service H\u00e9matologie, Nantes University Hospital, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Samarut","sequence":"additional","affiliation":[{"name":"Neurotraumatology and Neurosurgery Department, Nantes University Hospital, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9182","authenticated-orcid":false,"given":"Bastien","family":"Jamet","sequence":"additional","affiliation":[{"name":"CRCI2NA, INSERM UMR1307, CNRS-ERL6075, M\u00e9decine Nucl\u00e9aire, CHU Nantes, Universit\u00e9 de Nantes, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4270-5370","authenticated-orcid":false,"given":"Luc","family":"Ollivier","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut de Canc\u00e9rologie de L\u2019Ouest (ICO), F-44800 Saint-Herblain, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Bouda","sequence":"additional","affiliation":[{"name":"IRIS GRIM-Site de Saint-Herblain-Sant\u00e9 Atlantique, F-44800 Saint-Herblain, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"ref_1","first-page":"20190118","article-title":"Report of a Unique Case of Gemcitabine-Induced Radiation Recall Myelitis Following Spinal Cord Irradiation","volume":"6","author":"Masson","year":"2020","journal-title":"BJR Case Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and Checkpoint Blockade Immunotherapy: Radiosensitisation and Potential Mechanisms of Synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4049\/jimmunol.1200563","article-title":"Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation","volume":"189","author":"Gupta","year":"2012","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zhou, M., Wang, C., Lu, S., Xu, Y., Li, Z., Jiang, H., and Ma, Y. (2021). Tumor-Associated Macrophages in Cholangiocarcinoma: Complex Interplay and Potential Therapeutic Target. EBioMedicine, 67.","DOI":"10.1016\/j.ebiom.2021.103375"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Craciun, L., de Wind, R., Demetter, P., Lucidi, V., Bohlok, A., Michiels, S., Bouazza, F., Vouche, M., Tancredi, I., and Verset, G. (2020). Retrospective Analysis of the Immunogenic Effects of Intra-Arterial Locoregional Therapies in Hepatocellular Carcinoma: A Rationale for Combining Selective Internal Radiation Therapy (SIRT) and Immunotherapy. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6613-1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.3390\/curroncol28060384","article-title":"Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas","volume":"28","author":"Touchefeu","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/HEP.0000000000000544","article-title":"Chemotherapy with or without Selective Internal Radiation Therapy for Intrahepatic Cholangiocarcinoma: Data from Clinical Trials","volume":"79","author":"Edeline","year":"2024","journal-title":"Hepatology"},{"key":"ref_12","unstructured":"(2024, May 17). Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer|NEJM Evidence. Available online: https:\/\/evidence.nejm.org\/doi\/full\/10.1056\/EVIDoa2200015."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"KEYNOTE-966 Investigators. Pembrolizumab in Combination with Gemcitabine and Cisplatin Compared with Gemcitabine and Cisplatin Alone for Patients with Advanced Biliary Tract Cancer (KEYNOTE-966): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.canrad.2023.08.008","article-title":"Is Oligometastatic Disease an Applicable and Useful Concept in Haematologic Malignancies? A Narrative Review of Radiation Therapy Standards, Modern Techniques, and Innovations","volume":"28","author":"Ollivier","year":"2024","journal-title":"Cancer Radiother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, Treatment, and Response Assessment in Solitary Plasmacytoma: Updated Recommendations from a European Expert Panel","volume":"11","author":"Caers","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1080\/10428194.2019.1605067","article-title":"New Insights in the Treatment of Patients with Solitary Bone Plasmacytoma","volume":"60","author":"Mheidly","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/13543784.2021.1955103","article-title":"Immune Checkpoint Inhibitors for the Treatment of Myeloma: Novel Investigational Options","volume":"30","author":"Moreau","year":"2021","journal-title":"Expert. Opin. Investig. Drugs"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/382\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:47:29Z","timestamp":1760111249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/9\/382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["curroncol31090382"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31090382","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,9,2]]}}}